Caris Life Sciences (United States)
CAI
$28.50
+9.40%
Caris Life Sciences, Inc. is a next-generation AI TechBio company that develops and commercializes solutions to transform healthcare through comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Operating in the biotechnology industry, the company focuses on precision medicine, offering advanced molecular profiling and diagnostic services. As a relatively new public entity (listed in June 2025), Caris is positioned as an innovator in the AI-driven healthcare space, leveraging its proprietary data and algorithms to enable personalized treatment decisions. The current investor narrative centers on the company's rapid revenue growth and recent strategic momentum, but also on its volatile post-IPO trading history and the market's reassessment of growth expectations, as evidenced by recent tech sector sell-offs and the stock's significant price swings.…
CAI
Caris Life Sciences (United States)
$28.50
Investment Opinion: Should I buy CAI Today?
Rating: Buy. Caris Life Sciences offers a high-growth opportunity in the AI-driven precision medicine space, with revenue growing 78.8% YoY and a clear path to profitability. The average analyst target of $27.00 implies 7.7% upside, but the high target of $36.00 suggests 43.6% potential return if the company executes well. The company's strong balance sheet (current ratio 7.85) and positive operating margin (5.6%) support the bullish thesis.
Sign up to view all
CAI 12-Month Price Forecast
The AI assessment leans bullish given the company's exceptional revenue growth and near-profitability, but confidence is medium due to the high valuation and execution risks. The stock's recent surge reflects positive momentum, but sustaining this requires continued growth and profitability. If the company delivers on Q2 earnings and maintains growth above 70%, the bullish stance would be reinforced; however, any miss could trigger a sharp correction. Monitoring key metrics like revenue growth rate and gross margin will be crucial.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Caris Life Sciences (United States)'s 12-month outlook, with a consensus price target around $27.54 and implied upside of -3.4% versus the current price.
Average Target
$27.54
0 analysts
Implied Upside
-3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$22 - $36
Analyst target range
The target price range spans from a low of $22.00 to a high of $36.00, indicating a wide dispersion in expectations. The high target of $36.00 aligns with the stock's 52-week high and implies a potential return of 43.6% from the current price, suggesting that some analysts believe the company can achieve strong growth and multiple expansion. Conversely, the low target of $22.00 represents a downside of 12.2%, reflecting concerns about competitive pressures, execution risks, or a potential slowdown in growth. The wide spread between the low and high targets (63.6% difference from the low) signals significant uncertainty about the company's future performance. Recent ratings have been consistently positive, with no downgrades observed in the institutional ratings data, which suggests that analysts are maintaining their bullish stance despite the stock's volatility. However, the lack of a clear consensus recommendation and the moderate average target indicate that the market is still evaluating the company's long-term potential.
Bulls vs Bears: CAI Investment Factors
Caris Life Sciences presents a compelling growth story with exceptional revenue expansion and a clear path to profitability, supported by a strong balance sheet and positive analyst sentiment. However, the stock's elevated valuation, decelerating growth, and extreme volatility introduce significant risk. Currently, the bull case has stronger evidence given the recent momentum and near-breakeven profitability, but the sustainability of growth and the ability to meet aggressive earnings expectations remain the central tension. If revenue growth continues at a robust pace and the company achieves sustained profitability, the stock could re-rate higher; conversely, any miss on growth or profitability could trigger a sharp de-rating given the high multiple.
Bullish
- Explosive Revenue Growth: Revenue surged 78.8% YoY in Q1 2026 to $216.2M, up from $120.9M in Q1 2025. This rapid expansion demonstrates strong market adoption of its precision medicine and AI-driven diagnostics.
- Near Profitability Achieved: Q1 2026 net loss was only -$0.5M, with EPS of -$0.0018, a dramatic improvement from -$102.6M loss in Q1 2025. The company is on the cusp of turning profitable, supported by a positive operating margin of 5.6%.
- Strong Balance Sheet Liquidity: Current ratio of 7.85 indicates ample short-term liquidity to fund operations and growth initiatives. This reduces near-term solvency risk despite negative trailing earnings.
- Positive Analyst Sentiment: All 12 analysts maintain positive ratings with no downgrades. The average price target of $27.00 implies 7.7% upside, while the high target of $36.00 suggests 43.6% potential return.
Bearish
- High Valuation Despite Losses: PS ratio of 9.38x is steep for a company with negative trailing EPS. Forward PE of 66.35x implies the market expects substantial earnings growth, leaving little room for disappointment.
- Revenue Growth Deceleration: YoY growth slowed from 78.8% in Q1 2026 to 61.6% in Q4 2025 (calculated from $181.4M to $292.9M). This deceleration trend may continue as the revenue base expands.
- Extreme Price Volatility: Stock has a max drawdown of -62.98% and a 1-year decline of -31.03%, underperforming the S&P 500 by 49.7% over the same period. This volatility reflects high risk and speculative trading.
- Dependence on Future Profitability: Trailing EPS is -$0.07, and the company has a history of losses. The forward PE of 66.35x is based on estimated EPS of $0.925, which may be optimistic given execution risks.
CAI Technical Analysis
Caris Life Sciences has exhibited a highly volatile price history since its IPO in June 2025. Over the past year, the stock has declined 31.03%, reflecting a significant downtrend from its 52-week high of $36.65. As of September 4, 2026, the stock trades at $25.07, which is approximately 68% of its 52-week range (calculated as (25.07 - 14.19) / (36.65 - 14.19) = 0.68), indicating it is closer to the lower end of its range but has recovered substantially from its low. This positioning suggests that while the stock has been under pressure, it is showing signs of a potential recovery, though it remains below its highs, indicating lingering bearish sentiment or profit-taking after recent gains.
Beta
—
—
Max Drawdown
-63.0%
Largest decline past year
52-Week Range
$14-$35
Price range past year
Annual Return
-13.9%
Cumulative gain past year
| Period | CAI Return | S&P 500 |
|---|---|---|
| 1m | +30.7% | -2.4% |
| 3m | +59.6% | +2.2% |
| 6m | +51.5% | +14.8% |
| 1y | -13.9% | +14.6% |
| ytd | +5.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAI Fundamental Analysis
Caris Life Sciences has demonstrated robust revenue growth, with the most recent quarter (Q1 2026) reporting revenue of $216.17 million, a 78.78% increase year-over-year. This growth is a continuation of a strong upward trajectory, as revenue has grown from $120.92 million in Q1 2025 to $216.17 million in Q1 2026, with sequential increases from $181.40 million in Q2 2025 to $292.89 million in Q4 2025. The growth is driven by the company's core molecular profiling services and AI-driven solutions, which are gaining traction in the precision medicine market. However, the revenue growth rate has decelerated from the 78.78% YoY in Q1 2026, as Q4 2025 saw a 61.6% increase from the prior year quarter (calculated from $181.40M to $292.89M), indicating a potential slowdown in the pace of expansion.
Quarterly Revenue
$216174000.0B
2026-03
Revenue YoY Growth
+78.8%
YoY Comparison
Gross Margin
65.4%
Latest Quarter
Free Cash Flow
$123456000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAI Overvalued?
Given that Caris Life Sciences has negative trailing twelve-month net income (EPS of -$0.07), the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE ratios are not meaningful for unprofitable companies. The current PS ratio is 9.38x, based on a market cap of $7.62 billion and trailing twelve-month revenue of approximately $812 million (calculated from quarterly revenues: $216.17M + $292.89M + $216.83M + $181.40M = $907.29M, but using the provided PS ratio implies TTM revenue of $812M, which may be adjusted). The forward PE ratio of 66.35x suggests that analysts expect significant earnings growth, as the company is projected to become profitable, with estimated EPS of $0.925 for the next fiscal year. This wide gap between trailing losses and forward profitability indicates the market is pricing in a substantial turnaround, which is a high-risk expectation.
PE
-14.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
632.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant due to the company's history of losses and high valuation. Trailing EPS is -$0.07, and while Q1 2026 showed near-breakeven results, the company still relies on external funding for growth. The debt-to-equity ratio of 0.66 indicates moderate leverage, and interest expenses of $12.8M in Q1 2026 could pressure margins if rates rise. The negative net margin of -66.2% over the trailing twelve months highlights the challenge of converting revenue to profit, though recent quarters show improvement. Cash flow is positive (FCF TTM of $123.5M), but the high PS ratio of 9.38x leaves little room for error; any slowdown in growth could lead to multiple compression and significant downside.
FAQ
Key risks include: 1) Financial risk: negative trailing EPS and high valuation leave little room for error; 2) Competitive risk: the precision medicine market is crowded, and new entrants could pressure growth; 3) Macro risk: high-beta stock sensitive to tech sell-offs, as seen in the 1-year decline of -31%; 4) Company-specific risk: dependence on successful commercialization and regulatory approvals. The most severe risk is a growth slowdown, which could lead to a de-rating and significant downside.
Analysts have a 12-month average target of $27.00, with a range of $22.00 to $36.00. Our base case scenario (45% probability) sees the stock trading between $25 and $30, driven by continued strong growth but decelerating. The bull case (30% probability) targets $30-$36 if growth accelerates and profitability is achieved. The bear case (25% probability) could see the stock fall to $18-$22 if growth disappoints. The most likely scenario is the base case, assuming revenue growth remains above 60%.
CAI is trading at a PS ratio of 9.38x, which is high compared to the broader market but may be justified given its rapid growth. The forward PE of 66.35x indicates the market expects significant earnings growth, implying the stock is not cheap. Compared to its own history, the stock is below its 52-week high of $36.65, suggesting it may be undervalued relative to its peak, but still above the low of $14.19. The valuation implies the market expects continued strong growth and eventual profitability.
CAI offers a compelling risk/reward for growth-oriented investors, with revenue growing 78.8% YoY and a clear path to profitability. The average analyst target of $27.00 implies 7.7% upside, but the high target of $36.00 suggests 43.6% potential return. However, the stock is volatile and trades at a high PS ratio of 9.38x, so it is not suitable for risk-averse investors. A good buy for those who believe in the long-term potential of AI-driven precision medicine and can tolerate short-term fluctuations.
CAI is more suitable for long-term investment given its high growth potential and volatility. The stock has a beta that is likely high, as evidenced by its 1-month surge of 52% and 1-year decline of -31%, making it risky for short-term trading. For long-term investors, the company's AI-driven precision medicine platform has significant market potential, and if it achieves sustained profitability, the stock could appreciate substantially. A minimum holding period of 3-5 years is recommended to ride out volatility and allow the growth story to unfold.